Presented at ASH21: In the phase 1 EXPLORER trial, avapritinib, a selective KIT inhibitor, was generally well tolerated and elicited durable clinical and molecular responses in patients with advanced systemic mastocytosis MPNsm ASH22
This phase 1, open-label study comprised a dose-escalation phase and a dose-expansion phase . During dose escalation, patients received oral avapritinib at starting doses ranging from 30 to 400 mg QD in continuous 28-d treatment cycles. Dose escalation followed a 3 + 3 design until the MTD or RP2D was determined. During part 1, intra-patient dose escalation to assess dose levels not exceeding the MTD was allowed.
In the event a patient was withdrawn from study drug administration or the follow-up phase of the study, the medical monitor was informed. If there was a medical reason for withdrawal, the patient remained under the supervision of the investigator or designee until the condition returned to baseline or stabilized.
The safety population included all enrolled patients and was used to report AEs and PROs . The dose-determining population included all patients in a cohort in part 1 who received ≥21 prescribed avapritinib doses in C1 and completed follow-up through C1, or experienced DLT. The determination of the MTD and RP2D were based on the dose-determining population.
Spleen response was determined for patients with baseline splenomegaly and was assessed by palpation or spleen volume by imaging ; presence of either criterion was considered a response. DOR started at the first evidence of a response in any evaluable C-finding and ended at the time a response was lost . For patients who were still responding at the time of analysis, DOR was censored at the latest time point that the patient is assessed as having clinical improvement or better.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
NASA’s Imaging X-Ray Polarimetry Explorer (IXPE) Celebrates 1 Year of Exploring the CosmosNASA’s Imaging X-ray Polarimetry Explorer (IXPE) lit up the early morning sky one year ago as it started its journey into space. The satellite was launched on December 9, 2021, atop a SpaceX Falcon 9 rocket from NASA’s Kennedy Space Center in Florida. IXPE is the first satellite dedicated to meas
Consulte Mais informação »
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial - Nature MedicineIn a prespecified interim analysis of a pivotal phase 2 trial, tisagenlecleucel, an autologous CD19-targeting CAR-T cell therapy, produced a high rate of complete responses with a manageable safety profile in adults with relapsed or refractory follicular lymphoma
Consulte Mais informação »
Effect of air pollution on the human immune system - Nature MedicineInhaled particulates from environmental pollutants accumulate in macrophages in lung-associated lymph nodes over years, compromising immune surveillance via direct effects on immune cell function and lymphoid architecture. These findings reveal the importance of improved air quality to preserve immune health against current and emerging pathogens.
Consulte Mais informação »
Activists dressed as birds and trees rally for nature at COP15 in MontrealHundreds of people on Saturday braved sub-zero temperatures to march the streets of Montreal, the host city of this year's U.N. biodiversity summit, demanding a strong new deal to protect nature worldwide.
Consulte Mais informação »
Investor group launches campaign to help companies protect natureHere's the plan: Select 100 companies whose business burdens nature. Then, offer advice on how to lighten their impact and monitor their progress.
Consulte Mais informação »
Kit Gives Your Old Toyota Fortuner A Modern Lexus Makeover | CarscoopsBefore and after shots reveal the extent of the upgrades to turn the Toyota Hilux SUV into a Lexus Fortuner
Consulte Mais informação »